Latest News - DexCom
Top Corporates Hub
DexCom
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
23.07.2026 14:00
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
21.07.2026 13:40
Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
2 Cash-Heavy Stocks on Our Buy List and 1 We Avoid
21.07.2026 11:02
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup
11.07.2026 10:10
DEXCOM INC (DXCM) shows strong growth with 27% EPS growth and healthy fundamentals, paired with a promising technical breakout setup near $75.38. A compelling blend of quality and timing for growth investors.
Investors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassured
09.07.2026 15:15
Bell Global Equities Fund, managed by Bell Asset Management, released its May investor update. A copy of the letter can be downloaded here. The global equity market continued its rally in May, driven by accelerating AI infrastructure spending and a stronger-than-expected earnings season. The Fund (Platform Class) returned 2.1%, underperforming the MSCI World ex-Australia Index’s 4.5% […]
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
09.07.2026 12:30
SAN DIEGO, July 09, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be
Heald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Users
09.07.2026 12:30
Consumers purchasing Dexcom Stelo or Abbott Lingo through Heald now receive complimentary access to AI-powered glucose insightsALPHARETTA, Ga., July 09, 2026 (GLOBE NEWSWIRE) -- Heald, a digital metabolic health platform, today announced that consumers who purchase a Dexcom Stelo or Abbott Lingo continuous glucose monitor (CGM) through Heald will now receive complimentary access to the company's AI-powered Glucose Intelligence. The announcement expands access to personalized glucose insights for
Insulet launches Omnipod 5 in Spain
07.07.2026 11:10
A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.
DexCom (NASDAQ:DXCM): An Affordable Growth Pick With Strong Momentum and Financial Health
06.07.2026 08:50
DexCom (DXCM) fits the Growth at a Reasonable Price (GARP) strategy, offering strong earnings growth, reasonable valuation, and solid financial health as an affordable growth stock.
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down
02.07.2026 08:52
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
DexCom: The Growth Thesis Still Needs To Be Proven
02.07.2026 02:10
DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis.
3 Nasdaq 100 Stocks with Promising Prospects
01.07.2026 14:33
The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance and delivering strong returns.
Piper Sandler Raises its Price Target on DexCom (DXCM)
22.06.2026 09:22
DexCom, Inc. (NASDAQ:DXCM) is one of the 12 High Quality Stocks to Buy for the Long Term. On June 15, 2026, Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $88 from $75 and maintained an Overweight rating on the shares. O’Brien said Piper Sandler updated some of its […]
FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children
12.06.2026 15:44
https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children
DexCom Expands Beyond CGMs With CONNECT Results AI Apps And Nutrisense Deal
12.06.2026 10:16
DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced product updates, including an AI-enabled reimagined app experience and the Stelo app focused on metabolic health. DexCom also announced a planned acquisition of Nutrisense to expand its personalized nutrition and metabolic health guidance offering. DexCom is best known for continuous glucose...
3 Reasons Investors Love DexCom (DXCM)
11.06.2026 13:29
DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six months. At the same time, the S&P 500 has returned 6.9%.
Mizuho Maintains Outperform on DexCom, Raises Price Target to $85
09.06.2026 09:27
Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $75 to $85.
DexCom Inc (NASDAQ:DXCM) Passes Rigorous Quality Screen with Strong Profitability and Growth Metrics
08.06.2026 11:10
DexCom (DXCM) excels in quality investing metrics with 11.89% revenue CAGR, 47.12% ROIC, and minimal debt. Strong fundamentals and cash flow make it a standout in diabetes care.
Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff
08.06.2026 05:08
Inspire Medical Systems faces a sharp revenue slowdown due to temporary CPT coding and CMS Project WISeR disruptions. See why I rate INSP stock a Buy.
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
04.06.2026 16:10
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?